Drug intelligence / Profile preview

clobetasol + spironolactone

Development stage: Unknown
Lead developer: Trade
Modality: Small Molecules
Administration: Topical

Overview

Clobetasol + spironolactone is a topical combination medication that has been studied for preventing skin atrophy associated with corticosteroid use. Clobetasol is a potent topical glucocorticoid that can cause skin thinning (epidermal atrophy) as a side effect. Spironolactone, a mineralocorticoid receptor antagonist, has been shown to limit this clobetasol-induced skin atrophy when co-applied. The combination works by allowing the therapeutic benefits of clobetasol while the spironolactone component helps protect against the skin-thinning side effects through mineralocorticoid receptor blockade.

Targets

MR (Mineralocorticoid receptor)GR (Glucocorticoid receptor)

Beyond the preview

Go deeper on clobetasol + spironolactone.

Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from study design and recruitment through results.

Trial phase
Status
Readouts

Indications & development

Explore development by indication, patient population, and geography.

Indications
Development status
Countries

Licensing & deals

Trace asset ownership, licensing agreements, and commercial partnerships.

Partners
Deal terms
Milestones

Patents & exclusivity

Explore the patent landscape and regulatory exclusivity around an asset.

Patents
Expiration dates
Exclusivity

Competitive landscape

Compare development programs by target, modality, and indication.

Competing assets
Targets
Development stage

Research & analysis

Connect source evidence and development news to your research questions.

Publications
News
Analysis

Bring the full picture into focus.

See how Gosset can support your research on clobetasol + spironolactone.

Explore the full profile